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Abstract
Background: Buruli ulcer, caused by Mycobacterium ulcerans, is a localized skin lesion that can progress to
extensive ulceration and necrosis if left untreated. Unpublished studies of hydrated clays for therapeutic, topical
treatment of Buruli ulcer suggest that specific clay mineral products may have beneficial effects on wound healing.
In this study, we evaluated the in vitro antibacterial activity of a panel of clay mixtures and their derivative leachates
against M. ulcerans and assessed the in vivo efficacy of topically-applied, hydrated clays on Buruli ulcer progression
in mice infected with M. ulcerans.
Methods: M. ulcerans 1615 was incubated with 10 % suspensions of CB07, CB08, CB09, CB10, and BY07 clay
mixtures, and survival was determined over 28 days. For animal experiments, we examined the effect of topical
hydrated clay therapy on Buruli ulcer progression in vivo in mouse tails subcutaneously infected with M.
ulcerans 1615.
Results: The CB07, CB08, and CB09 clays exhibited bactericidal activity against M. ulcerans after 7, 14, 21, and
28 days of incubation. In contrast, clay leachates exhibited inhibitory, bacteriostatic effects on M. ulcerans
growth in vitro. After establishing an ulcerative M. ulcerans infection for three months, ulcerated regions of
the tails were treated once daily (five consecutive days per week) for 22 days with hydrated CB09 clay
poultices. Mice in the clay treatment group exhibited healing as assessed by gross morphological changes
and a reduction in M. ulcerans present in the wounds.
Conclusions: These data reveal that specific clays exhibit in vitro bactericidal activity against M. ulcerans and that
hydrated clay poultices may offer a complementary and integrative strategy for topically treating Buruli ulcer disease.
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Background
Buruli ulcer, a skin disease caused by Mycobacterium
ulcerans, is the world’s third most common mycobacter-
ial infection after tuberculosis and leprosy [1]. The
macrolide exotoxin, mycolactone, is a key M. ulcerans
virulence factor and plays a central role in Buruli ulcer
pathology [2]. After M. ulcerans infection is established,
Buruli ulcer appears as a painless nodule in the skin. Left
untreated, M. ulcerans destroys skin, subcutaneous fat,
and sometimes bone [3–6]. Gradually, an ulcer develops
with a necrotic center and undermined edges, sur-
rounded by an indurated area [6–8].
Buruli ulcer occurs primarily in resource-poor areas
where limited access and the cost of seeking health care
can be prohibitive. Given that the disease symptoms are
generally painless, some patients do not seek treatment
until the disease has progressed to the ulcerative stage
[1, 3, 9]. M. ulcerans infection can be effectively man-
aged with a combination antibiotic therapy of rifampi-
cin and streptomycin or rifampicin and clarithromycin
[10–12]. Lesions may also spontaneously heal by un-
known mechanisms [1, 8]. In the ulcerative stage of dis-
ease, M. ulcerans infection is generally treated by
surgical removal of infected and surrounding healthy
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skin and tissue, pre- and post-surgical antibiotic admin-
istration, and subsequently may require grafting of
healthy skin tissue [13]. Cure from the disease is expen-
sive, time consuming, causes scarring and tissue dam-
age, and may result in deformities and disabilities.
Moreover, despite free of charge biomedical care and
support for Buruli ulcer patients in Cameroon, non-
medical costs, productivity losses, and social isolation
cause patients to abandon in-patient hospitalization
and medical treatment [14]. A topical, therapeutic strat-
egy that complements existing treatment options and is
socially acceptable in parts of the world where Buruli
ulcer is problematic would be desirable [14, 15].
Previously, topical application of hydrated clay poul-
tices was observed to be effective in treating and pro-
moting healing of infected tissue in Buruli ulcer patients
[16]. In the uncontrolled, observational study, either
green illite or green montmorillonite clays were hydrated
and applied daily as a 2-cm thick poultice with an
overlay of 10-30 cm beyond the ulcer. After months of
topical treatment, the ulcers were minimized, and the in-
fections often healed with some soft tissue scarring [16].
Haydel et al. [17] subjected the two clay minerals used
in the above study to in vitro antimicrobial susceptibility
testing, demonstrating effects ranging from enhanced
microbial growth to complete growth inhibition of
several pathogenic and non-pathogenic bacteria. These
patient observations [16] and in vitro microbiological
data [17] imply that topical application of hydrated clays
or other absorptive materials could potentially be an
effective, inexpensive, and complementary treatment
option for Buruli ulcer. However, the effect of hydrated
clays on M. ulcerans growth in vitro or during in vivo in-
fection remains unknown. In this study, we examined
the effect of different clay mixtures and their derivative
leachates on M. ulcerans growth in vitro. We also ex-
amined the effect of antimycobacterial clay treatment
on Buruli ulcer progression in vivo in a mouse tail
model of infection.
Methods
M. ulcerans growth
M. ulcerans 1615 was obtained from Dr. Pamela Small
(University of Tennessee, Knoxville, TN, USA). Bacteria
were grown on Middlebrook 7H10 agar (Difco) supple-
mented with 10 % oleic acid-bovine serum albumin-
dextrose-catalase (OADC), 0.05 % Tween 20, and 0.5 %
glycerol (supplemented M7H10 agar) at 32 °C. Bacterial
inocula were serially passaged through a 25-guage needle
to disrupt mycobacterial clumps, diluted in PBS (pH 7.4)
to obtain the desired concentration based on OD600
measurements, and quantified by plating on supple-
mented M7H10 agar to determine viable colony forming
units (CFU).
Clay mixtures and clay mixture leachate preparation
Antibacterial, mineralogical, and chemical characteristics
of the CB07, CB08, CB09, CB10, and BY07 clay mixtures
and derived leachates have been previously described
[18–20]. The CB clay mixtures are all composed of
approximately 52 % clays and 48 % non-clay minerals
[20]. The most abundant clay mineral in all of the CB
samples is illite-smectite (36–37 %), followed by mont-
morillonite (9.7–14.2 %) and kaolinite (1.4–3.6 %). The
most abundant non-clay mineral present in the CB sam-
ples is quartz (34–37.3 %), followed by pyrite (4–5.5 %)
and jarosite (2.4–4.7 %) [20]. The most abundant min-
erals present in the BY07 clay mixture are Ca-smectite
clay (37.3 %), followed by anorthoclase feldspar (23.0 %)
and quartz (13.7 %) [19]. All clay mixtures were steril-
ized by autoclaving for 1 h at 121 °C prior to experimen-
tal use. Derived leachates were obtained by vigorously
stirring clay mixtures (1 g/20 ml) in sterile, deionized
H2O (dH2O) for 24 h. Subsequently, the hydrated clay
mixture suspensions were centrifuged (31,000 × g) for
3 h at 4 °C to separate insoluble and soluble fractions.
The aqueous supernatant (leachate) was collected and
sterilized by passage through a 0.22 μm filter.
In vitro antimicrobial susceptibility testing
M. ulcerans 1615 were exposed to CB07, CB08, CB09,
CB10, and BY07 clay mixtures or derived leachates [18, 19],
and survival was determined by enumerating colonies on
supplemented M7H10 agar plates. Briefly, 100 mg of steril-
ized clay minerals were added to late-logarithmic phase M.
ulcerans in supplemented M7H9 broth (1 ml), and the
bacteria-clay suspensions were incubated at 32 °C on a ro-
tating drum. To assess antimicrobial activity of leachates,
late-logarithmic phase M. ulcerans 1615 was pelleted, re-
suspended in 1 ml of CB07, CB08, CB09, CB10, or BY07
clay leachates, water, or supplemented M7H9 broth, and in-
cubated at 32 °C on a rotating drum. Experimental samples
and controls were collected on 0, 7, 14, 21, and 28 days,
subjected to 10-fold serial dilutions, plated on supple-
mented M7H10 agar, and incubated at 32 °C to determine
viable CFU. Bactericidal activity is defined as the ability to
kill bacteria, while bacteriostatic activity means that the
agent prevents the growth of bacteria. Minimal bactericidal
concentration (MBC) is defined as the lowest concentration
of a particular antibacterial agent that kills ≥ 99.9 % of the
bacterial population in a liquid medium.
Bacterial inoculum preparation for in vivo studies
To determine the M. ulcerans 1615 inoculum required to
establish a visible ulcer, groups of four female BALB/c
mice, aged four to six weeks, were injected in the tail with
103, 105, or 107 CFU of M. ulcerans in 30 μl PBS. Aliquots
of M. ulcerans 1615 inoculum, grown in supplemented
Adusumilli and Haydel BMC Complementary and Alternative Medicine  (2016) 16:40 Page 2 of 8
M7H9 broth to late-logarithmic phase of growth, were
prepared as described above.
Animal infection procedures and bacterial enumeration of
M. ulcerans-infected mouse tails
A total of 30 four- to-six week old female BALB/c mice
(Charles River Laboratories) were subcutaneously
injected in the tail with ~106M. ulcerans 1615 cells in
30 μl of PBS. During M. ulcerans inoculation, the mice
were anesthetized by intraperitoneal injection of 0.05 ml
per 25 g of body weight with a mixture containing
21 mg ketamine, 2.4 mg xylazine, and 0.3 mg aceproma-
zine. Five additional mice injected with PBS served as
negative controls. On day one post inoculation, five mice
infected with M. ulcerans were euthanized, and the tails
were used to enumerate M. ulcerans in the infected
animals. Briefly, tails were minced with blades, ground
with a Potter-Elvehjem homogenizer in 0.15 M NaCl,
and decontaminated with an equal volume of N-acetyl-
L-cysteine sodium hydroxide. Aliquots of serial dilutions
were plated on supplemented M7H10 agar, and the
plates were incubated at 32 °C for 8-10 weeks. Mice
were monitored daily. Of the 25 remaining animals in-
fected with M. ulcerans, only 15 animals developed a
visible ulcer. Five animals were euthanized to enumerate
bacterial load before treatment, and the remaining 10
animals were either treated with hydrated clay poultices
(n = 5) or left untreated (n = 5). All animal experiments
were carried out in strict accordance with the recom-
mendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health.
All animal procedures were approved by the Arizona
State University Animal Care and Use Committee (pro-
tocols 09-1030R and 12-1240R) and conducted accord-
ing to relevant national and international guidelines.
Topical application of hydrated clay poultices
Approximately three months postinfection, mice were
either treated with hydrated clay at the site of infection
or cleansed with sterile saline (no treatment). Mice in
the clay treatment group (n = 5) were treated with hy-
drated CB09 clay (~0.2 grams clay mixed with 100 μl
sterile dH2O) at the site of M. ulcerans infection. During
topical application of hydrated clay poultices, mice were
restrained using a commercial acrylic mouse restrainer.
The infected area of the tail was initially washed with
cotton swabs dipped in sterile dH2O. Subsequently, a
sterile cotton swab was used to evenly apply a thick
poultice of hydrated clay to the site of infection. Infected
and treated tails were then covered with Tegaderm
waterproof transparent dressings followed by an adhe-
sive bandage to prevent the mice from disturbing and
removing the clay poultice. For five consecutive days per
week, the Tegaderm dressing and adhesive bandages
were removed, and the infected tails were cleansed with
sterile dH2O. After gentle washing to remove the clay
poultice, freshly hydrated clay was applied, and the tails
were redressed with bandages. Mice in the no treatment
group (n = 5) did not undergo any treatment at the site
of M. ulcerans infection. Similar to the infected and
treated animals, the infected area of the tails of mice in
the no treatment group was subjected to gentle washing
with sterile water and subsequent redressing with Tega-
derm and an adhesive bandage for five consecutive days
per week. Decreased erythema and ulceration and reduc-
tion in bacterial load were considered indicators of
wound healing. Two animals, one in the clay treatment
group and one in the no treatment group, developed
secondary infections and were euthanized prior to the
end of the study. After 22 days of treatment, the
remaining eight mice were euthanized. To enumerate
bacterial load, the tails of the euthanized animals were
removed aseptically, weighed, and homogenized as de-
scribed above. The number of viable M. ulcerans cells in
the tissue was determined by plating serial dilutions on
supplemented M7H10 agar. The CFU were counted
after 8-10 weeks of incubation at 32 °C and expressed as
CFU/g tissue.
Statistical analyses
We used ANOVA with Tukey’s or Dunnett’s multiple
comparisons to assess statistical significance. Each P
value was adjusted to account for multiple comparisons
of mean values across groups. Data were analyzed using
GraphPad Prism 6.
Results
Clays are bactericidal to M. ulcerans in vitro
A 10 % suspension of clays was tested for in vitro bac-
tericidal activity against M. ulcerans. Of the five different
clays tested, CB07 and CB09 exhibited complete M.
ulcerans bactericidal activity within 7 days of exposure,
while CB08 required 14 days of exposure to yield
complete bactericidal activity (Fig. 1). BY07 required
21 days to demonstrate complete bactericidal activity,
while exposure to CB10 only minimally inhibited M.
ulcerans growth over 28 days (Fig. 1).
Effect of aqueous clay leachates on M. ulcerans growth
in vitro
To differentiate the bactericidal effect of the soluble
ions released from the clay particles, we examined the
effect of aqueous leachates on growth of M. ulcerans.
Leachates, which contain water-leachable components
of the clay mixtures, were prepared and assayed for
antibacterial activity against M. ulcerans. Compared to
M. ulcerans growth inhibition during water incubation,
CB08 leachate (CB08-L), CB09 leachate (CB09-L), and
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CB10 leachate (CB10-L) did not exhibit inhibitory ac-
tivity over 28 days, and in some cases, incubation with
the leachates enhanced M. ulcerans viability (Fig. 2).
In contrast, incubation with CB07 leachate (CB07-L)
and BY07 leachate (BY07-L) resulted in increasing
and significant bactericidal activity (p < 0.0001) over
28 days (Fig. 2).
Development and progression of M. ulcerans in mouse
tails
A pilot study was conducted to determine the optimal
inoculum of M. ulcerans that would induce a visible
ulcer in mouse tails. BALB/c mice were infected with
7.9 × 103, 1.0 × 105 CFU, or 1.6 × 107M. ulcerans CFU.
By the second week of infection, all three groups of ani-
mals developed swelling and erythema in the tails
around the area of inoculation. Although the swelling
subsided after the third week of infection, there was per-
sistent erythema in all three groups. By 36 days postin-
fection, mice in the 105 and 107 groups developed small
pinpoint ulcers on their tails. By three months postinfec-
tion, mice in the 107 inoculum group developed the
most pronounced ulcers.
Therapeutic effect of hydrated clay on Buruli ulcer
progression in mice
Since the clays had a bactericidal effect on M. ulcerans
growth in vitro, we examined the effect of hydrated
clay on progression of M. ulcerans infection in vivo.
BALB/c mice were subcutaneously infected in the tails
with an inoculum of 1.5 × 106M. ulcerans CFU. By the
second week of infection, mice developed swelling and
Fig. 1 Effect of clay mixtures on M. ulcerans growth in vitro. M. ulcerans was incubated with a 10 % suspension of clay in supplemented M7H9
broth at 32 °C. After 7, 14, 21, and 28 d, survival was determined by plating samples on supplemented M7H10 agar and incubation at 32 °C to
determine viable CFU. M. ulcerans growth in supplemented M7H9 broth is shown as a control. Data represent three independent experiments
performed in triplicate, and results are expressed as mean ± SEM. ****, p < 0.0001; ANOVA, Tukey’s multiple comparisons
Fig. 2 Effect of aqueous clay leachates on M. ulcerans growth in vitro. M. ulcerans was exposed to 1 ml of supplemented M7H9 broth (control),
sterile deionized H2O, or clay leachates. At specified times, samples were plated on supplemented M7H10 agar and incubated at 32 °C to
determine viable CFU. Data represent three independent experiments performed in triplicate, and results are expressed as mean ± SD. Statistically
significant differences, compared to dH2O-incubated samples on corresponding days, are shown. ***, p < 0.001; ****, p < 0.0001; ANOVA, Tukey’s
multiple comparisons
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erythema in the tails around the area of M. ulcerans in-
oculation. Although the swelling subsided after the third
week of infection, there was persistent erythema in tails
of all infected mice. During the course of treatment, one
mouse from the clay treatment group was euthanized
during the second week due to a secondary infection
resulting in purulent erythema of the tail. Similarly, one
mouse from the no treatment group was euthanized in
the fourth week due to a secondary infection. Approxi-
mately three months post infection, affected areas of the
mouse tails were either left untreated (no treatment
group, n = 4) or treated with hydrated CB09 clay (clay
treatment group, n = 4) for 22 days (Fig. 3). As seen in
Fig. 3, mice in the no treatment group (panel a) had
increased erythema and progression of ulcer when
compared to the clay treatment mice (panel b). In the
Fig. 3 Gross morphology and bacterial detection of M. ulcerans-infected mouse tails with and without topical application of hydrated clay mixtures.
Disease advancement and gross morphology of M. ulcerans-infected tails following 22 d of daily cleansing with sterile dH2O (no treatment) (a) or daily
topical applications of hydrated antibacterial CB09 clay (b). After 22 d of topical treatment with the hydrated CB09 clay mixture, M. ulcerans survival
was determined by collecting the tails from infected mice, processing the samples as described in the methods, and inoculating supplemented
M7H10 agar to determine viable CFU per gram of tissue for each animal sample (c). Error bars represent the SD from three viable CFU determinations
for each animal sample. The average (± SD) number of M. ulcerans cells, as determined from five infected animals on day 1 post-infection, is shown for
comparison. The limit of detection is 10 CFU. NT, no treatment; CT, clay treatment. ***, p < 0.001; ****, p < 0.0001; ANOVA, Tukey’s multiple comparisons
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clay treatment group, three of the four mice had
decreased erythema (Fig. 3). Tails collected from three
of the four mice in the clay treatment group yielded
no M. ulcerans growth after plating on supplemented
M7H10 medium and incubation at 32 °C for eight
weeks (Fig. 3c). In contrast, M. ulcerans was detected
in the tails of untreated mice (Fig. 3c).
Discussion
The World Health Organization recommends combin-
ation antibiotic therapy of rifampicin and streptomycin
or rifampicin and clarithromycin with or without surgery
(mainly debridement and skin grafting) for treating
Buruli ulcer [12]. Since there is currently no specific vac-
cine against Buruli ulcer [21], an effective topical treat-
ment option that is cost-friendly and easy to use could
be welcomed in resource-poor settings where Buruli
ulcer is endemic [14, 22]. Several topical therapeutic
options for Buruli ulcer have been investigated, includ-
ing 40 °C heat therapy, phenytoin, clay bandages, and
creams containing nitrogen oxides [16, 23–27]. Heat
treatment and creams delivering topical nitrogen oxides
promoted healing in Buruli ulcer patients [23, 24, 28].
Nitric oxide was also shown to kill M. ulcerans in vitro
[24, 25]. When applied therapeutically, phenytoin pow-
der did not kill M. ulcerans but promoted healing
through acceleration of fibrogenesis [27]. Hyperbaric
oxygen at a partial pressure of 2.5 kPa was beneficial in
healing mice infected with M. ulcerans [29].
In an uncontrolled and unpublished study, Buruli
ulcer patients at a treatment center in Zouan-
Hounien, Ivory Coast were treated with hydrated clay
minerals [16]. The described debridement phase fo-
cused on hydrated illite clay-mediated removal of nec-
rotic tissue and cleansing of the surrounding tissues.
In the scarring phase, a hydrated poultice of mont-
morillonite clay was applied to the wounds and
appeared to promote tissue regeneration [16]. After
several months of clay applications, Buruli ulcer
wounds were reportedly healed in most of the patients
[16]. However, clay therapy was not further investi-
gated in a controlled clinical trial.
In the present study, we investigated the effect of anti-
bacterial clay minerals and clay aqueous leachates on M.
ulcerans growth in vitro and the therapeutic effect on
Buruli ulcer progression in vivo in a mouse model of M.
ulcerans infection. Two of the five clays tested exhibited
complete in vitro bactericidal activity against M. ulcerans
within 7 days, while two clay mineral leachates demon-
strated complete in vitro bactericidal activity within
28 days. In contrast, compared to incubation in water,
some of the leachates appeared to provide a nutritional
benefit to M. ulcerans. While the four CB samples are
mineralogically similar, there are notable differences as-
sociated with the composition of ions bound to their
surfaces [20]. For example, exchangeable copper concen-
trations ranged from 0.04 mM (CB09-L), 0.10 mM
(CB08-L), 0.19 mM (CB10-L) to 3.18 mM (CB07-L), an
approximate 80-fold difference in concentration across
the four samples [20]. While we have established that
clay-mediated killing of Escherichia coli and methicillin-
resistant Staphylococcus aureus (MRSA) is attributed to
toxicity associated directly with released metal ions
(Fe2+, Cu2+, and Zn2+) in an acidic environment [20, 30],
it is unknown if these ions are important for killing
M. ulcerans in vitro. Moreover, while 10 % suspensions
of the CB clays completely killed E. coli and MRSA
in vitro within 24 h [20], the CB10 clay (10 % sus-
pension) reduced viability by ~1 log10 after 28 d, but
did not completely kill M. ulcerans (Fig. 1). Further
investigations associated with the chemical differences
of the CB clays could provide some insight into why
the CB10 clay exhibits minimal antibacterial activity
against M. ulcerans.
The effects of hydrated clay minerals on M. ulcerans
growth and wound progression in infected mice are
likely due to a combination of both physical and chem-
ical characteristics of clay minerals. Clays are small phyl-
losilicate minerals that are commonly grouped into
three main classes – smectite, illite and kaolinite – based
on their overall crystal layer structure and expandability.
Smectite minerals, which include montmorillonite clay,
exhibit high expansion (swelling) capabilities in the pres-
ence of water [31]. Conversely, illite and kaolinite are
non-expanding clays [31]. We have previously assessed
the ability of different hydrated clays to treat MRSA-
infected superficial, cutaneous wounds in mice [32]. We
demonstrated that natural and ion-exchanged illite clays
performed best, as measured by bacterial load, inflam-
matory response and gross wound morphology with sig-
nificant decreases in bacterial viability and dermatitis
[32]. Topical application of kaolinite clay was the least
effective, resulting in the lowest decrease in bacterial
load and exhibiting severe dermatitis [32]. Although the
CB09 clay mixture used in this study is a heterogeneous
mixture of illite-smectite, montmorillonite, kaolinite,
and non-clay minerals with different structural and
expansion properties [32], daily application and removal
of the clay poultices could diminish M. ulcerans growth
due to an unfavorable chemical environment and could
result in physical removal of M. ulcerans and/or myco-
lactone via adsorption. Mycolactone plays a central role
in the pathogenesis of M. ulcerans and is thought to
be responsible for most of the tissue destruction that
occurs in a Buruli ulcer wound [2]. In macrophages,
fibroblasts, and epithelial and endothelial cells, myco-
lactone blocks Sec61-dependent protein translocation
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into the endoplasmic reticulum, leading to degrad-
ation of aberrantly-located proteins [33], so reduction
or removal of mycolactone during daily application and
removal of clay poultices would be beneficial for promot-
ing a proinflammatory response and wound healing.
Notably, there are several limitations of this study. The
number of animals developing ulcers and available for
topical treatment was small. Of the 25 animals infected
with M. ulcerans, only 15 animals developed a visible
ulcer within two to three months postinfection, suggest-
ing that the 10 mice without a visible ulcer or lesion
were insufficiently inoculated. After euthanizing five
mice for quantitative assessment of M. ulcerans present
in the tail wounds, 10 mice were available for treatment.
Subsequently, one mouse in the no treatment group and
one mouse in the clay treatment group developed super-
infections, so only four mice remained in each group.
While the three mice in the clay treatment group were
negative for M. ulcerans growth, homogenate samples
were not tested by PCR. Previous studies indicate that
human tissue specimens deemed culture negative yielded
positive PCR results, suggesting persistance of mycobac-
terial material [10, 34]. In the absence of PCR testing, it
is unknown if mycobacterial material persisted in the
mouse tail samples deemed culture negative. As deter-
mined by clinical improvement and reduction of bacter-
ial burden, three mice were successfully treated with
CB09 clay poultices. However, in the absence of systemic
antibiotic therapy, it is possible that disease recurrence
could occur at the original site of infection. A longer
study is necessary to investigate recurrence-free healing
of Buruli ulcer after topical treatment with hydrated
antibacterial clay.
Conclusions
Several clays with demonstrated antibacterial activity
against Gram-negative and Gram-positive pathogens
also exhibit in vitro bactericidal activity against M. ulcer-
ans. Mice treated with hydrated antibacterial clay healed
M. ulcerans lesions in vivo, as assessed by changes in
gross morphology and bacterial enumeration, suggesting
that clay minerals or other similar adsorptive/absorptive
materials may be of value in the complementary and
integrative management of Buruli ulcer lesions. Since
natural, mineralogically-identical clay samples exhibit
variability in chemical composition and in vitro antibac-
terial activity [20], we are pursuing customized and
nanostructured porous, absorptive materials, which
offer standard composition and controlled antibacterial
efficacy, for topical treatment of M. ulcerans infections.
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